Found: 9
Select item for more details and to access through your institution.
Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma.
- Published in:
- Respiratory Research, 2011, v. 12, n. 12, p. 1, doi. 10.1186/1465-9921-12-160
- By:
- Publication type:
- Article
Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebocontrolled trial.
- Published in:
- Respiratory Research, 2011, v. 12, n. 10, p. 1, doi. 10.1186/1465-9921-12-132
- By:
- Publication type:
- Article
Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial.
- Published in:
- Clinical Autonomic Research, 2021, v. 31, n. 6, p. 699, doi. 10.1007/s10286-021-00827-0
- By:
- Publication type:
- Article
A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease.
- Published in:
- Cough (17459974), 2005, v. 1, p. 3, doi. 10.1186/1745-9974-1-3
- By:
- Publication type:
- Article
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
- Published in:
- 2019
- By:
- Publication type:
- journal article